risks of glp 1 agonists GLP-1 In Obesity Benefit-Risk Assessment of GLP-1 Receptor
Description
The FDA-approved oral formulation (Rybelsus for diabetes, Wegovy pill for weight loss) has been clinically validated but requires much higher doses than injectable versions
Additionally, tirzepatide demonstrates bias at the GLP1R, favoring the synthesis of cAMP over the recruitment of -arrestin [1]
2016;11:e0166275
Jura, N., Archer, H
Shima Hadidchi MD Family Practice, we closely monitor all patients using these medications to ensure safety and effectiveness
A.WeikopP.GrahamD
